Compare MNKD & FMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNKD | FMC |
|---|---|---|
| Founded | 1991 | 1910 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2004 | 1994 |
| Metric | MNKD | FMC |
|---|---|---|
| Price | $3.85 | $10.03 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 13 |
| Target Price | $8.69 | ★ $18.50 |
| AVG Volume (30 Days) | ★ 4.7M | 3.7M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.18% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $348,966,000.00 | ★ $4,727,800,000.00 |
| Revenue This Year | $35.81 | $7.89 |
| Revenue Next Year | $11.89 | $4.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $2.23 | $10.56 |
| 52 Week High | $6.51 | $42.77 |
| Indicator | MNKD | FMC |
|---|---|---|
| Relative Strength Index (RSI) | 47.65 | 35.48 |
| Support Level | $3.81 | N/A |
| Resistance Level | $3.94 | $12.37 |
| Average True Range (ATR) | 0.21 | 0.51 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 34.25 | 4.41 |
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.